文献速递真实世界研究与卫生经济

拉丁美洲临床流行病学网络系列——第8篇:在智利急性冠脉综合征中替格瑞洛相比氯吡格雷具有成本效果

Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile.
PubMed 文献 · J Clin Epidemiol · 2016-10-27

该研究基于Markov模型,从支付方角度评估替格瑞洛替代氯吡格雷用于智利急性冠脉综合征二级预防的增量成本效果比。安全性和有效性数据来自系统综述,成本以2013年智利比索计。结果显示,替格瑞洛相比氯吡格雷的ICER为每获得一个质量调整生命年4,893,126智利比索(约合9,689美元),结论为替格瑞洛具有成本效果。

要点

  • 替格瑞洛相比氯吡格雷的ICER为每QALY 4,893,126智利比索(约9,689美元)。
  • 预算影响分析中,替格瑞洛额外成本5,233,854,272智利比索,获得979个QALY。
  • 作者结论认为替格瑞洛在智利急性冠脉综合征二级预防中具有成本效果。

核心结论

  • 替格瑞洛相比氯吡格雷用于急性冠脉综合征二级预防具有成本效果。
  • 该发现与其他国际成本效果研究报道相似。

研究设计与样本

  • 基于Markov模型的成本效果分析,从支付方角度进行。
  • 替格瑞洛的安全性和有效性数据来自系统综述。
  • 成本以2013年智利比索表示。
  • 进行了包含折扣率和国家成本变异性的概率敏感性分析。
  • 进行了2015年预算影响分析以计算两种治疗的总成本。

主要发现

  • 折扣率6%时,替格瑞洛相比氯吡格雷的ICER为每获得一个QALY 4,893,126智利比索(约合9,689美元)。
  • 预算影响分析基线场景下,考虑100%治疗、覆盖和依从性,替格瑞洛相比氯吡格雷额外成本为5,233,854,272智利比索,获得979个QALY。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the incremental cost-effectiveness ratio (ICER) of the use of ticagrelor as a substitute for clopidogrel for secondary prevention of acute coronary syndrome in Chile. STUDY DESIGN AND SETTING: Cost-effectiveness analysis based on a Markov model: Safety and effectiveness data of ticagrelor were obtained from a systematic review of the literature. Costs are expressed in Chilean pesos (CLP) as of 2013. The evaluation was conducted from the payer standpoint. A probabilistic sensitivity analysis comprising discount rates and national cost variability was done. A budget impact analysis estimated for 2015 was conducted to calculate the total cost for both treatments. RESULTS: The ICER with a discount rate of 6% for ticagrelor vs. clopidogrel was CLP 4,893,126 per quality-adjusted life-year (QALY) gained (=9,689 US$). In the budget impact analysis for the baseline scenario, considering 100% of treatment, coverage, and adherence, ticagrelor represented an additional cost of CLP 5,233,854,272, for 979 QALYs gained compared with clopidogrel. CONCLUSIONS: Ticagrelor is cost-effective in comparison with clopidogrel for the secondary prevention of acute coronary syndrome. These findings are similar to those reported in other international cost-effectiveness studies.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. De la Puente C, Vallejos C, Bustos L, et al. Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile. J Clin Epidemiol. 2016. PMID: 27989953. doi:10.1016/j.jclinepi.2016.04.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。